

ISOGENICA ANNOUNCES PROMOTION OF DR BILL ELDRIDGE TO CHIEF SCIENTIFIC OFFICER Cambridge, UK. May 20th, 2021

Isogenica Ltd, a leader in the use of synthetic biology and in vitro display for the discovery and optimisation of novel biotherapeutics, announced today that Dr William (Bill) Eldridge has been promoted to Chief Scientific Officer.

Since joining Isogenica as Senior Director of Antibody Alliances in January 2020, Dr Eldridge has played a leading role in delivering Isogenica's multi-target antibody discovery collaborations and in the securing of valuable new partnerships benefiting our businesses growth.

"Bill has been central in transforming our discovery operations and providing oversight on new initiatives that position Isogenica for further growth based on our expertise in single-domain antibody therapeutics," said Emma Sceats, Chief Executive Officer of Isogenica.

"His knowledgeable and thoughtful leadership and people-first approach has been a great strength in guiding our company through the challenges of the COVID-19 pandemic. I am certain that Bill will continue this trajectory as Chief Scientific Officer and I look forward to working with him to build upon Isogenica's success."

Dr Bjoern Cochlovius, Chairman of Isogenica added, "Bill's extensive experience in drug discovery and development, and his passion for translating science into effective new medicines for patients, make him well-suited for his new role at Isogenica."

Before joining Isogenica, Dr Eldridge held numerous senior leadership roles at Cambridge Antibody Technology (now Astra Zeneca) and Cyclogenix, working in antibody, scaffold protein and peptide discovery and development, developing early candidates into leads for preclinical studies. Dr Eldridge started his career at Pfizer after completing a Medical Research Council funded PhD at the University of Kent.

"Having started my career at Isogenica it's an honour to now serve the company as its Chief Scientific Officer" said Dr Eldridge. "Isogenica's synthetic antibody libraries are opening up so many targets and new epitopes and creating new possibilities to intervene in disease biology. I'm excited to lead the company into its next phase, where our innovation will be focused to the creation of highly developable candidate therapeutic antibodies that our partners can accelerate into the clinic."

About Isogenica

Isogenica is an antibody discovery biotechnology company specializing in single-domain antibody therapeutics. These small format antibodies can be readily incorporated into gene and cell therapies, antibody-drug conjugates and bi- and multi-specific antibody therapeutics making them a



ISOGENICA LTD
The Mansion House
Chesterford Research Park
Little Chesterford
Essex CB10 1XL

T +44 1799 533 680
E info@isogenica.com

ISOGENICA.COM 

highly versatile platform for drug development. The company's fully synthetic single domain library is designed from the DNA up to eliminate liabilities and improve the biophysical traits of library antibodies. Combined with CIS Display, Isogenica's proprietary antibody display platform which enables the full diversity of the company's massive libraries to be displayed, the company has a unique and proven engine for therapeutic antibody discovery and development. Working in collaboration with biopharmaceutical partners over the last decade the company has developed a deep pipeline including two clinical stage assets and more than ten partnered pre-clinical and discovery stage programmes.

For more information, visit: www.isogenica.com

Contact:

Mandeep Sehmi, Business Development

T: +44 1799 533 680

E: mandeep.sehmi@isogenica.com

Isogenica Limited is a registered company in England & Wales, with the company no. 3571781.

Registered at The Mansion House, Chesterford Research Park, Little Chesterford, Essex CB10 1XL.